Clinical Diagnosis

A team of investigators has conducted ocular pharmacokinetic studies, including metabolism, providing valuable information for ocular drug development.

A team of investigators examined the association between COVID-19 transmissibility and elapsed time since infection, and found that SARS-CoV-2 may still be transmissible 10 days post-infection.

Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.

The future of this age-related condition is bright and in focus.

A new treatment option may increase basal tear production in patients.

Faricimab is the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

The study reviews the outcomes following penetrating, closed trauma–related injuries.

The historic eye institute celebrates six decades of leadership in eye care research, education and clinical practice.

Organization makes a commitment to expand translational research acceleration program and fund career development award.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

Renewed consumer interest in and demand for LASIK, SMILE, and other procedures are among the key drivers for 2021 performance.

According to the companies, the trial will evaluate the safety, tolerability, and immune response of the vaccine that can be administered as a primary shot and a booster.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.

Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.

Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.

Numerous studies have shown that adherence declines with more complex regimens of more than 1 or 2 bottles.

Investigators find the prevalence of ocular surface tumors is greater in the North Central region of the United States.

Canadian researchers have found that rapid antigen tests to detect the SARS-CoV-2 virus are associated with a very low rate of false positive results.

A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.

According to the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories.

Physicians find that additional treatment is not required for many patients.

A University of California Davis study shows that small serving of the fruit increased protective pigments in the eye.

According to the company, biped.ai includes a comfortable and lightweight collar fitted with 3d cameras that continuously monitor a 170° field of view for the user detecting, tracking and predicting the trajectories of all surrounding elements a few seconds in advance.

According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.

The pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US, has received positive feedback from glaucoma surgeons involved in the trial.